P L Moriearty
Overview
Explore the profile of P L Moriearty including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
149
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moriearty P, Seubert P, Galasko D, Markwell S, Unni L, Vicari S, et al.
Methods Find Exp Clin Pharmacol
. 1999 Dec;
21(8):549-54.
PMID: 10599054
Development of neuropathology in Alzheimer's disease (AD) cannot be studied directly in living patients. Therefore, concentrations in cerebrospinal fluid (CSF) of the proteins tau, A beta 42, alpha 1-ACT, apoE...
2.
Oh M, Power J, Thompson L, Moriearty P, Disterhoft J
J Neurosci
. 1999 Feb;
19(5):1814-23.
PMID: 10024365
The effects of metrifonate, a second generation cholinesterase inhibitor, were examined on CA1 pyramidal neurons from hippocampal slices of young and aging rabbits using current-clamp, intracellular recording techniques. Bath perfusion...
3.
Moriearty P, Chen S, Catchpole M, Lu H
Chin Med J (Engl)
. 1998 Oct;
110(12):899-906.
PMID: 9772398
Objective: To identify aspects of the health of Chinese women throughout their lifespan which may paradoxically be threatened by modernization and to suggest relevant interventions through medical practice, education and...
4.
Becker R, Colliver J, Markwell S, Moriearty P, Unni L, Vicari S
Alzheimer Dis Assoc Disord
. 1998 Apr;
12(1):54-7.
PMID: 9539412
Forty-seven patients with probable Alzheimer disease (AD) completed a 6-month double-blind study to compare metrifonate with placebo. The Alzheimer Disease Assessment Scale cognitive subscale score of the metrifonate group treated...
5.
Moriearty P, Schmidt B, Disterhoft J
Behav Neurosci
. 1998 Feb;
111(5):1031-40.
PMID: 9383522
The cholinergic system is known to show deterioration during aging and Alzheimer's disease (AD). In response, a therapeutic approach to AD has been to attempt to compensate for the decrease...
6.
Moriearty P, Ralph M, Becker R, Schmidt B, Thompson L, Disterhoft J
Pharmacol Biochem Behav
. 1997 Jan;
56(1):103-10.
PMID: 8981616
The cholinergic system is known to show deterioration during aging and Alzheimer's disease. In response, a therapeutic approach to Alzheimer's disease has been to attempt to compensate for the decrease...
7.
Becker R, Colliver J, Markwell S, Moriearty P, Unni L, Vicari S
Alzheimer Dis Assoc Disord
. 1996 Jan;
10(3):124-31.
PMID: 8876775
Fifty patients with probable Alzheimer disease (AD) completed a 3-month double-blind study to compare metrifonate to placebo. We dosed metrifonate to achieve a 40-60% inhibition of red blood cell acetylcholinesterase...
8.
Moriearty P, Thornton S, Becker R
Methods Find Exp Clin Pharmacol
. 1993 Jul;
15(6):407-12.
PMID: 8231460
Transdermal delivery of cholinesterase inhibitors (ChEI) for treatment of dementia would have advantages associated with continuous dosing and enhanced compliance, but feasibility depends on achieving desired levels of central nervous...
9.
Moriearty P, Chen S
Chin Med J (Engl)
. 1993 Apr;
106(4):243-9.
PMID: 8325151
This article reviews, for authors publishing in the Chinese literature, the characteristics of MEDLINE users, the format of MEDLINE citations and the main retrieval strategies used with the system. References...
10.
Moriearty P, Becker R
Methods Find Exp Clin Pharmacol
. 1992 Oct;
14(8):615-21.
PMID: 1494302
Heptylphysostigmine (HPTL), a derivative of the AChE inhibitor physostigmine (PHY), is under investigation as a therapeutic agent in Alzheimer's disease. HPTL is active against human RBC AChE both in vitro...